Please try another search
Context Therapeutics Inc. is a biopharmaceutical company focused on improving the lives of patients living with solid tumors. The Company is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors. Its preclinical program, CTIM-76, is an anti-Claudin 6 x anti-CD3 (CLDN6xCD3) antigen bispecific monoclonal antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, lung, and testicular, and absent from or expressed at low levels in healthy adult tissues. CTIM-76 is a Claudin 6 and CD3 bispecific antibody capable of binding to tumor cells expressing Claudin 6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement. Claudin 6 is expressed on multiple solid tumors such as ovarian, lung and testicular.
Name | Age | Since | Title |
---|---|---|---|
Richard Jay Berman | 79 | 2021 | Independent Chairman of the Board |
Martin A. Lehr | 38 | 2015 | Co-Founder, President, CEO & Director |
Linda B. West | 64 | 2021 | Independent Director |
Jennifer Evans Stacey | 58 | 2021 | Independent Director |
Philip W. Kantoff | 68 | 2018 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review